Evidence that abnormally large seasonal declines in vitamin D status may trigger SLE flare in non-African Americans

Abstract

Cross-sectional studies have shown that low vitamin D (25-hydroxyvitamin D (25(OH)D)) is associated with increased systemic lupus erythematosus (SLE) activity. This study is the first to assess the temporal relationship between 25(OH)D levels and onset of SLE flare. This assessment was made possible because of the specimen bank and database of the Ohio SLE Study (OSS), a longitudinal study of frequently relapsing SLE that involved regular bimonthly patient follow-up. We identified for this study 82 flares from 46 patients that were separated by at least 8 months from previous flares. Serum 25(OH)D levels were measured at 4 and 2 months before flare, and at the time of flare (a flare interval). We found that for flares occurring during low daylight months (LDM, Oct-Mar), 25(OH)D levels were decreased at the time of flare, but only in non-African American (non-AA) patients (32% decrease at flare, compared to 4 months prior, p < 0.001). To control for seasonal effects, we also measured 25(OH)D levels in the LDM “no-flare” intervals, which were intervals that matched to the same calendar months of the patients’ LDM flare intervals, but that didn’t end in flare (n = 24). For these matches, a significant decrease occurred in 25(OH)D levels during the flare intervals (18.1% decrease, p < 0.001), but not during the matching no-flare intervals (6.2% decrease, p = 0.411). For flares occurring during high daylight months (HDM), 25(OH)D levels changed only in non-AA patients, increasing slightly (5.6%, p = 0.010). Analysis of flare rates for the entire OSS cohort (n = 201 flares) revealed a tendency for higher flare rates during LDM compared to HDM, but again only in non-AA patients (p = 0.060). Flare rates were lower during HDM for non-AA patients compared to AA patients (p = 0.028). In conclusion, in non-AA SLE patients, unusually large declines in 25(OH)D during LDM may be mechanistically related to SLE flare, whereas relatively high 25(OH)D levels during HDM may protect against flare.

Keywords

Vitamin D systemic lupus erythematosus disease flare

Get full access to this article

View all access options for this article.

References

Holick

. Vitamin D deficiency. N Engl J Med 2007; 357: 266–281.

Rosen

. Clinical practice. Vitamin D insufficiency. N Engl J Med 2011; 364: 248–254.

Hsia

Heiss

Ren

. Calcium/vitamin D supplementation and cardiovascular events. Circulation 2007; 115: 846–854.

Swales HH, Wang TJ. Vitamin D and cardiovascular disease risk: emerging evidence. Curr Opin Cardiol 2010; 25: 513–517.

Pilz

Tomaschitz

Ritz

Pieber

. Vitamin D status and arterial hypertension: a systematic review. Nat Rev Cardiol 2009; 6: 621–630.

Noonan

Koch

Nakane

. Differential effects of vitamin D receptor activators on aortic calcification and pulse wave velocity in uraemic rats. Nephrol Dial Transplant 2008; 23: 3824–3830.

Freedman

Wagenknecht

Hairston

. Vitamin d, adiposity, and calcified atherosclerotic plaque in african-americans. J Clin Endocrinol Metab 2010; 95: 1076–1083.

Razzaque

. The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011; 79: 708–714.

Kovesdy

Kalantar-Zadeh

. Vitamin D receptor activation and survival in chronic kidney disease. Kidney Int 2008; 73: 1355–1363.

10.

Melamed

Michos

Post

Astor

. 25-hydroxyvitamin D levels and the risk of mortality in the general population. Arch Intern Med 2008; 168: 1629–1637.

11.

Shoben

Rudser

de Boer

Young

Kestenbaum

. Association of oral calcitriol with improved survival in nondialyzed CKD. J Am Soc Nephrol 2008; 19: 1613–1619.

12.

Dobnig

Pilz

Scharnagl

. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008; 168: 1340–1349.

13.

Garami

Cheng

Gardner

. 1,25(OH)2 vitamin D3, and retinoic acid antagonize endothelin-stimulated hypertrophy of neonatal rat cardiac myocytes. J Clin Invest 1996; 97: 1577–1588.

14.

Qiao

Uskokovic

Xiang

Zheng

Kong

. Vitamin D: a negative endocrine regulator of the renin-angiotensin system and blood pressure. J Steroid Biochem Mol Biol 2004; 89–90: 387–392.

15.

Freundlich

Quiroz

Zhang

. Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394–1402.

16.

Zhang

Ning

Deb

Kong

. Combination therapy with AT1 blocker and vitamin D analog markedly ameliorates diabetic nephropathy: blockade of compensatory renin increase. Proc Natl Acad Sci U S A 2008; 105: 15896–15901.

17.

Hypponen

Boucher

Berry

Power

. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 2008; 57: 298–305.

18.

Patel

Gutierrez

Andress

Coyne

Levin

Wolf

. Vitamin D deficiency and anemia in early chronic kidney disease. Kidney Int 2010; 77: 715–720.

19.

Agarwal

Acharya

Tian

. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823–2828.

20.

Zhang

Yuan

Sun

. 1,25-Dihydroxyvitamin D3 targeting of NF-kappaB suppresses high glucose-induced MCP-1 expression in mesangial cells. Kidney Int 2007; 72: 193–201.

21.

Zehnder

Quinkler

Eardley

. Reduction of the vitamin D hormonal system in kidney disease is associated with increased renal inflammation. Kidney Int 2008; 74: 1343–1353.

22.

Jablonski

Chonchol

Pierce

Walker

Seals

. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension 2011; 57: 63–69.

23.

Agmon-Levin

Blank

Zandman-Goddard

. Vitamin D: an instrumental factor in the anti-phospholipid syndrome by inhibition of tissue factor expression. Ann Rheum Dis 2011; 70: 145–150.

24.

Nettis

Colanardi

Loria

Vacca

. Acquired C1-inhibitor deficiency in a patient with systemic lupus erythematosus: a case report and review of the literature. Eur J Clin Invest 2005; 35: 781–784.

25.

Dusso

Tokumoto

. Defective renal maintenance of the vitamin D endocrine system impairs vitamin D renoprotection: a downward spiral in kidney disease. Kidney Int 2011; 79: 715–729.

26.

Baeke F, Gysemans C, Korf H, Mathieu C. Vitamin D insufficiency: implications for the immune system. Pediatr Nephrol 2010; 10: 482–496.

27.

Baeke

Takiishi

Korf

Gysemans

Mathieu

. Vitamin D: modulator of the immune system. Curr Opin Pharmacol 2010; 10: 482–496.

28.

Bijl

Kallenberg

. Ultraviolet light and cutaneous lupus. Lupus 2006; 15: 724–727.

29.

Boonstra

Barrat

Crain

Heath

Savelkoul

O'Garra

. 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4(+) T cells to enhance the development of Th2 cells. J Immunol 2001; 167: 4974–4980.

30.

Rausch-Fan

Leutmezer

Willheim

. Regulation of cytokine production in human peripheral blood mononuclear cells and allergen-specific th cell clones by 1alpha,25-dihydroxyvitamin D3. Int Arch Allergy Immunol 2002; 128: 33–41.

31.

Griffin

Lutz

Phan

Bachman

McKean

Kumar

. Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its analogs: a vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 6800–6805.

32.

Chen

Sims

Chen

Lipsky

. Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007; 179: 1634–1647.

33.

Kamen

Aranow

. The link between vitamin D deficiency and sytemic lupus erythematosus. Curr Rheumatol Rep 2008; 10: 273–280.

34.

Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology 2011 published on 29 June 29 2011 doi:101093/rheumatology/ker212.

35.

Lewis

Hunsicker

Lan

S-P

Rohde

Lachin

the Lupus Nephritis Collaborative Study Group, including Hebert

. A controlled trial of plasmapheresis therapy in severe lupus nephritis. N Engl J Med 1992; 326: 1373–1379.

36.

Hay

Bacon

Gordon

. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993; 86: 447–458.

37.

Alarcon-Segovia

Tumlin

Furie

. LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003; 48: 442–454.

38.

Rovin

Tang

Sun

. Clinical significance of fever in the SLE patient receiving steroid therapy. Kidney Int 2005; 68: 747–759.

39.

Rovin

Song

Birmingham

Hebert

Nagaraja

. Urine chemokines as biomarkers of human systemic lupus erythematosus activity. J Am Soc Nephrol 2005; 16: 467–473.

40.

Birmingham

Nagaraja

Rovin

. Fluctuation in self-perceived stress and increased risk of flare in patients with lupus nephritis carrying the serotonin receptor 1A -1019 G allele. Arthritis Rheum 2006; 54: 3291–3299.

41.

Maxwell

. Seasonal variation in vitamin D. Proc Nutr Soc 1994; 53: 533–543.

42.

Birmingham

Rovin

Shidham

Bissell

Nagaraja

Hebert

. Relationship between albuminuria and total proteinuria in SLE nephritis: diagnostic and therapeutic implication. Clin J Am Soc Nephrol 2008; 3: 1028–1033.

43.

Shoenfeld

Amital

Shoenfeld

. The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease. Nat Clin Pract Rheumatol 2009; 5: 99–105.

44.

Kamen

Aranow

. Vitamin D in systemic lupus erythematosus. Curr Opin Rheumatol 2008; 20: 532–537.

45.

Albert

Proal

Marshall

. Vitamin D: the alternative hypothesis. Autoimmun Rev 2009; 8: 639–644.

46.

Adams

Sharma

Gacad

Singer

. Metabolism of 25-hydroxyvitamin D3 by cultured pulmonary alveolar macrophages in sarcoidosis. J Clin Invest 1983; 72: 1856–1860.

47.

Fritsche

Mondal

Ehrnsperger

Andreesen

Kreutz

. Regulation of 25-hydroxyvitamin D3-1 alpha-hydroxylase and production of 1 alpha,25-dihydroxyvitamin D3 by human dendritic cells. Blood 2003; 102: 3314–3316.

48.

Webb

Kline

Holick

. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988; 67: 373–378.

49.

Harris

. Vitamin D and African Americans. J Nutr 2006; 136: 1126–1129.

50.

Harris

Dawson-Hughes

. Seasonal changes in plasma 25-hydroxyvitamin D concentrations of young American black and white women. Am J Clin Nutr 1998; 67: 1232–1236.

51.

Craig

Curtis

. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. J Rheumatol 2010; 37: 275–281.

52.

Michos

Reis

Post

. Vitamin D deficiency is associated with increased risk of fatal stroke among whites but not blacks: the NHANES II linked mortality files [Abstract]. Circulation 2010; 122: A9478–A9478.

53.

Alarcon

Roseman

Bartolucci

. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. LUMINA Study Group. Lupus in minority populations, nature versus nurture. Arthritis Rheum 1998; 41: 1173–1180.

54.

Alarcon

Friedman

Straaton

. Systemic lupus erythematosus in three ethnic groups: III. A comparison of characteristics early in the natural history of the LUMINA cohort. LUpus in MInority populations: NAture vs. Nurture. Lupus 1999; 8: 197–209.